HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
HIV infection predisposes latent tuberculosis-infected (LTBI) subjects to active TB. This study is designed to determine whether HIV infection of LTBI subjects compromises the balanced Mycobacterium tuberculosis (Mtb)-specific T helper 17 (Th17) response of recognized importance in anti-TB immunity. Comparative analysis of Mtb- and cytomegalovirus (CMV)-specific CD4 T cell responses demonstrates a marked dampening of the Mtb-specific CD4 T cell effectors and polyfunctional cells while preserving CMV-specific response. Additionally, HIV skews the Mtb-specific Th17 response in chronic HIV-infected LTBI progressors, but not long-term non-progressors (LTNPs), with preservation of pro-inflammatory interferon (IFN)-γ/interleukin-17 (IL-17) and significant loss of anti-inflammatory IL-10/IL-17 effectors that is restored by anti-retroviral therapy (ART). HIV-driven impairment of Mtb-specific response cannot be attributed to preferential infection as cell-associated HIV DNA and HIV RNA reveal equivalent viral burden in CD4 T cells from different antigen specificities. We therefore propose that beyond HIV-induced loss of Mtb-specific CD4 T cells, the associated dysregulation of Mtb-specific T cell homeostasis can potentially enhance the onset of TB in LTBI subjects.
HIV-MTB Co-Infection Reduces CD4+ T Cells and Affects Granuloma Integrity.
Huang S, Liu M, Zhang H, Song W, Guo W, Feng Y Viruses. 2024; 16(8).
PMID: 39205309 PMC: 11360352. DOI: 10.3390/v16081335.
Olsson O, Tesfaye F, Sokilde R, Mazurek J, Abebe M, Yeba H Front Microbiol. 2022; 12:808250.
PMID: 35295678 PMC: 8920554. DOI: 10.3389/fmicb.2021.808250.
Jondle C, Johnson K, Mboko W, Tarakanova V J Virol. 2021; 95(20):e0072621.
PMID: 34346769 PMC: 8475519. DOI: 10.1128/JVI.00726-21.
Host-directed therapy to combat mycobacterial infections.
Kilinc G, Saris A, Ottenhoff T, Haks M Immunol Rev. 2021; 301(1):62-83.
PMID: 33565103 PMC: 8248113. DOI: 10.1111/imr.12951.